2014 - NTNU Discovery - Pdf-dokument och e-böcker Gratis

2021-04-05T15:36:37Z http://gupea.ub.gu.se/dspace-oai/request oai

Our lead investigational product, NM133, is a nano-enabled form of cyclosporine A which is being developed for the treatment of dry eye. IACTA Pharmaceuticals's Co-Founder & Chief Executive Officer is Damon Burrows. Other executives include William Pedranti, Co-Founder & Chief Administrative Officer; George Ng, Co-Founder & Chief Business Officer and 2 others. See the full leadership team at Craft. About IACTA Pharmaceuticals, Inc. IACTA is an ophthalmic focused pharmaceutical company led by former top executives from one of the leading eye care companies in the world, Allergan. IACTA Pharma understands that building a pharmaceutical company is more than just science and technology.

IACTA Pharmaceuticals and Zhaoke Ophthalmology agree to co-develop novel eye treatments July 30, 2020; New licensing agreement accelerates the development of IACTA Pharmaceuticals’ novel dry eye disease and allergic conjunctivitis treatments on China and Southeast Asia July 28, 2020 2021-01-07 · About IACTA Pharmaceuticals, Inc. IACTA is an ophthalmic focused pharmaceutical company led by former top executives from one of the leading eye care companies in the world, Allergan. IACTA Pharmaceuticals is a company focused on the development of therapeutics for the application in ophthalmology. Its product pipeline includes Syk kinase inhibitor, broad-spectrum ocular antibiotic, and topical cyclosporine for dry eye. IACTA Pharmaceuticals was established to develop and commercialize innovative eyecare products.

2021-04-05T15:36:37Z http://gupea.ub.gu.se/dspace-oai/request oai

Arbor Pharmaceuticals. Lung Therapeutics. Actuate Therapeutics. Azitra Immunome.

2021-04-05T15:36:37Z http://gupea.ub.gu.se/dspace-oai/request oai

and HONG KONG, July 28, 2020 /PRNewswire/ -- IACTA Pharmaceuticals, Inc. ("IACTA" or the "Company") and Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited ("ZKO"), a leading Hong Kong-based pharmaceutical company, today announces they have entered into a definitive license agreement on the licensing of two of the Company's products, IC 265 for dry eye and IC 270 for Iacta Pharmaceuticals Inc. USPTO Trademarks › Iacta Pharmaceuticals Inc. › Olivia Isabella Application #88889681.

For more About IACTA Pharmaceuticals, Inc. IACTA is an ophthalmic focused pharmaceutical company led by former top executives from one of the leading eye care companies in the world, Allergan. 2021-01-07 Explore IACTA Pharmaceuticals's investment information, scientific platforms, therapeutic approaches, indications and more here! Home. Data Dashboards . Top CEOs 2019/2020.
Industriteknik bas

We’re dedicated to treating diseases, advancing technology and improving patient outcomes.

Get notified when IACTA Pharmaceuticals posts new jobs. See similar jobs Create job alert.
Cut-off klausul

manuela widman
kompetensteamet 2021
hur många veckor får man ta studielån
svensk redovisning bokföringsboken
alvis campus nyköping
spanningshuvudvark engelska

Leif Edlund - Canal Midi

Delivering cutting-edge eye care products. | Our goal is to vastly improve patient care and outcomes by bringing innovative eye care technology IACTA Pharmaceuticals is targeting two therapeutic areas in ophthalmology — dry eye and ocular pain — where significant unmet need exists. The global eye care market is growing in size, however major pharmaceutical companies are reducing their internal R&D efforts, leaving a big gap in … 2021-01-07 IACTA Pharmaceuticals was established to develop and commercialize innovative eyecare products. We’re dedicated to treating diseases, advancing technology and improving patient outcomes. Our lead investigational product, NM133, is a nano-enabled form of cyclosporine A which is being developed for the treatment of dry eye using licensed proprietary Molecular Envelope Technology (MET). 2021-01-07 IACTA Pharmaceuticals and Zhaoke Ophthalmology Pharmaceutical (ZKO), a Hong Kong-based pharmaceutical company, announced they have entered into a definitive license agreement on the licensing of two of the company’s products, IC 265 for dry eye and IC 270 for allergic conjunctivitis.The exclusive license is for ophthalmic indications in China and other countries of Southeast Asia.